BIO Fills Top Executive Posts, Including Government Relations VP
The Biotechnology Industry Organization completed its reorganization under new President Jim Greenwood by formally naming five top executives April 28
You may also be interested in...
The Biotechnology Industry Organization will be working to ensure that the concerns about drug safety do not delay product approvals as a first priority under President James Greenwood
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials